

1 **Effect of *Bacillus coagulans* Unique IS-2 in Inflammatory Bowel Disease (IBD): A**
2 **Randomized Controlled Trial**

3
4 V Deepak Bamola¹, Divya Dubey¹, Projoyita Samanta¹, Saurabh Kedia², Ratna Sudha
5 Madempudi³, Jayanthi Neelamraju³, Vineet Ahuja², Rama Chaudhry^{1*}

6
7 ¹ Department of Microbiology, ² Department of Gastroenterology,
8 All India Institute of Medical Sciences, New Delhi, India

9 ³ Centre for Research & Development, Unique Biotech Ltd., Plot No. 2, Phase-II,
10 Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India

11 *Corresponding author

12
13 **Abstract**

14
15 Probiotic intervention is an important approach for the treatment and health
16 restoration in inflammatory bowel disease (IBD). The preventive and therapeutic effects of
17 probiotic *Bacillus coagulans* Unique IS-2 in different diseases have been well recognized but
18 its efficacy in IBD is unreported. Therefore, a study was conducted to assess the effect of
19 *Bacillus coagulans* Unique IS-2 in IBD patients. Subjects those satisfying compliance
20 criteria were recruited in the study and given either probiotic *B. coagulans* Unique IS-2 or
21 placebo for 4 weeks as per randomization. Survival of the given probiotic strain in GI,
22 presence of beneficial gut bacteria, serum cytokines, serum serotonin and serum dopamine,
23 symptoms of disease, physical, behavioral and psychological parameters of the subjects were
24 evaluated before and after intervention. In this study *B. coagulans* Unique IS-2 was well
25 tolerated with no severe adverse events in IBD patients. *B. coagulans* Unique IS-2
26 demonstrated good survival in GI tract by significantly high detection in probiotic treated
27 group (p <0.001). Significant enhancement in beneficial *Lactobacilli* was observed in
28 probiotic treated group (p <0.01). NGS data and metagenomic analysis also showed an
29 increase in the abundance of bacterial genera *Bacillus*, *Lactobacillus*, *Bifidobacterium*,
30 *Faecalibacterium*, *Bacteroides*, *Megamonas*, *Lachnospira*, *Blautia* and *Alistipes* in the post
31 intervention samples in the treatment group. A decrease in the abundance of bacterial
32 genera *Sutterella*, *Dialister*, *Roseburia* and *Megasphaera* was observed in post intervention
33 samples in the treatment group. Increased secretion of cytokine IL-10 and variable decrease
34 in the secretion of IL-6, IL-1 β , TNF- α , IL -17 and IL -23 was observed in in the probiotic
35 treated group. Post intervention change in serum serotonin and serum dopamine was not
36 significant in both the groups. A reduction in the severity of disease symptoms and
37 improvement in the physical, behavioral and psychological parameter was observed in the
38 probiotic treated group. The observed results demonstrated that *B. coagulans* Unique IS-2
39 with SMT was effective in adult IBD patients. Study was registered with Clinical Trials
40 Registry India (CTRI) - (registration reference- REF/2016/09/012181, CTRI registration
41 No.- CTRI/2019/11/022087).

42
43 **Keywords:** Inflammatory bowel disease (IBD), Gut Microbiota, Probiotic, *Bacillus*
44 *coagulans*, Cytokines, Randomized Controlled Trial (RCT)

Introduction

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79

Inflammatory bowel disease (IBD) is a gastrointestinal (GI) disease characterized by chronic inflammation. The incidence of IBD is rising all over the world ¹ including Asia ². Across the globe India is projected to have one of the highest IBD burden in spite of having lower prevalence as compared to the West ^{3, 4}. IBD significantly diminishes the quality of life of the affected individuals by disturbing health, daily work, education, and social relationships which cause a considerable impact on health and economy ⁵. Etiology and pathogenesis of IBD is multi-factorial and involves genetics, ethnicity, diet, lifestyle, environmental factors, immunity and gut microbiota of the individual ^{6, 7}. Studies have reported the higher stress level and disturbance in psychology in IBD patients may trigger the inflammation, increases the severity of disease ⁸.

The human gut microbes referred to as gut microbiota which has demonstrated physiological functions associated with homeostasis, nutrition, immunity and defense of the host. Normally the gut maintains a homeostatic condition but in IBD this homeostasis gets disturbed and leads to uncontrolled intestinal inflammation which involves tissue disruption and inflammation of the gut wall ⁹. Down-regulation of the immune responses may allow the damaged site to heal and reset the normal physiological functions ⁶. Alteration in the gut microbiota, referred to as dysbiosis, plays a key role in the pathogenesis of IBD ^{10, 11}. Usually dysbiosis occurs in both inflamed and non-inflamed areas in IBD patients ¹² and is well recognized sign of IBD ¹³. Studies have reported the modification of gut microbiota with probiotic intervention to attenuate inflammatory activity and prevent relapses in IBD and therefore probiotics are considered as an important approach for treatment and health restoration in IBD ^{14 11} by relieving intestinal dysbiosis and clinical efficacy on GI inflammation ¹⁰.

GI disorders modulate the gut function and influence the emotional and cognitive factors including mood, anxiety, pain and negative effects, decision making, restlessness. Therefore, the evaluation of these factors has turn out to be an important factor which needs to be monitored to reduce the severity of the disease. This change in emotional and cognitive factors may be associated with serum serotonin and dopamine in IBD patients ¹⁵. The lowering of serotonin levels can result in mood disorders, such as anxiety or depression and hence consider playing an important role in regulating physical and psychological symptoms ¹⁶ and activation of immune response and gut inflammation ¹⁵. Dopamine is also important neurotransmitter, which affect behavior, psychology, immune functions and gastrointestinal

80 functions etc. Studies reported its unregulated production in crohn's disease and ulcerative
81 colitis ¹⁷. Gut microbiota and probiotics have demonstrated the effect on behavior,
82 psychology, mood, and cognition ^{18, 19}.

83 *Bacillus* strains are stable at room temperature and hence gaining a lot of attention. *B.*
84 *coagulans* is a spore-forming, gram-positive, non-pathogenic, facultative anaerobic, lactic
85 acid-producing bacteria and resistant to high temperatures ²⁰. *B. coagulans* Qualified
86 Presumption of Safety (QPS) list ²¹ and has been reported Generally Recognized as Safe
87 (GRAS) and considered safe by European Union Food Safety Authority (EFSA) and US
88 Food and Drug Administration (FDA). *B coagulans* Unique IS-2 (ATCC PTA-11748,
89 MTCC 5260,) is a shelf-stable, resistant to bile acids and acidic conditions of the stomach,
90 clinically established probiotic strain and with proven safety and efficacy in the treatment of
91 constipation, diarrhea ^{22, 23, 24, 25} bacterial vaginosis ²⁶, and irritable bowel syndrome (IBS) ²⁷.
92 In this study we assessed the effect of *B coagulans* Unique IS2 on adults with inflammatory
93 bowel disease (IBD). Survival of the given probiotic *B coagulans* Unique IS2 in the gut,
94 presence of beneficial gut bacteria, serum cytokines, serotonin and dopamine, IBD
95 symptoms, physical and psychological parameters were evaluated before and after
96 intervention.

Methodology

- 97
98
99
- 100 ▪ **Study design** : Randomized, double blind, placebo controlled trial
 - 101 ▪ **Site**: Outpatients from a tertiary care hospital.
 - 102 ▪ **Ethical approval and written informed consent**: Ethical approval for the study was
103 obtained from Institute Ethics Committee of AIIMS, New Delhi, India (Ref –
104 IEC.478/07.10.2016.OP-7). Expected duration of participation, benefits that might be
105 expected from the study, associated risks, maintenance of confidentiality of records etc
106 were explained to each participant and a written informed consent was obtained before
107 enrollment in the study.
 - 108 ▪ **Subject / Selection of patients**: Clinically diagnosed adult patients of ulcerative colitis
109 (UC) with mild to moderate severity between age group (18–60 years) under standard
110 Medical treatment (SMT) patients were included. In this study the UC patient were
111 included. Simple Clinical Colitis Activity Index (SCCAI) score²⁸ was used to quantify
112 UC disease activity before and after intervention. SCCAI score was calculated by
113 evaluating different disease symptoms including bowel frequency, urgency of defecation,
114 blood in stool, abdominal cramps and general wellbeing of the patients. SMT for the
115 enrolled patient in this study was 5-aminosalicylic acid (5-ASA) - Sulfasalazine (3 grams/
116 day) or Mesalamine 800 mg orally 3 times a day.
 - 117 ▪ **Inclusion criteria**: (a) Adult patient clinically diagnosed with Ulcerative Colitis (UC), (b)
118 patients of either sex of the age range from 18-60 year, (d) patient ready to participate in
119 the study and giving written consent, (e) patient visiting to Out Patient Department (OPD)
120 of AIIMS for treatment.
 - 121 ▪ **Exclusion criteria**: (a) Patient diagnosed with any kind of carcinoma, (b) Patient
122 diagnosed with any other gastrointestinal disease, (c) Patient suffering from
123 Immunodeficiency disorder, (d) Patient is taking any probiotic drug/ or having consumed
124 probiotic in the last one month, (e) patient not taking food through oral route, (f) Patient
125 having undergone any kind of gastrointestinal surgery in the last three month.
 - 126 ▪ **Enrolment of patients**: After establishing the eligibility on screening, a total of 100
127 patients were recruited and randomized. Patients were called for baseline visit (day 0).
128 Medical history, medications, physical examination and vital signs were assessed during
129 hospital visit. *B. coagulans* Unique IS-2 (2billion-CFU/capsule) twice in day (total 4
billion CFU / per day) or placebo (matching in size and appearance, contained only

130 excipient, maltodextrin) twice in a day was given to qualified patients for 4 weeks
131 followed by observation and telephonic follow-up of dose compliance.

132 ■ **Sample size determination:** Statistical software STATA (Version 14, USA) was used for
133 sample calculation. To identify presence of proportion difference the assumption was
134 made that minimum of 118 subjects required to be screened and 94 patients required
135 assessing the endpoint in the study which will reject the null hypothesis.

136 ■ **Intervention:** Fully characterized FDA / DCGI/ FSSAI approved probiotic strain *Bacillus*
137 *coagulans* Unique IS-2 (ATCC PTA-11748, MTCC 5260) was used as an intervention
138 agent in this study for 4 weeks along with placebo as per randomization. The patients
139 were explained to consume one capsule post meal twice a day for 4 weeks along with the
140 SMT. The compliance was ensured by telephonic follow-up and scheduled hospital visits.

141 ■ **Randomization:** Computerized permuted blocks randomization was done in 1:1 ratio and
142 generated by nQuery clinical trial design platform / Sample Size Software. It consisted of
143 two phases: screening, baseline visit 1 (week 0 / day 0), visit 2 (1 week after completing
144 intervention / week 5). The randomization codes were kept blinded.

145 ■ **Outcome measures:** The efficacy outcomes were measured by (i) detection of *Bacillus*
146 *coagulans* Unique IS-2 after administration, (ii) Change in beneficial Lactobacillus and
147 other gut microbiota after probiotic intervention, (iii) Change in pro and anti-inflammatory
148 cytokines after probiotic intervention, (iv) Change in symptoms of the disease, (v) Change
149 in serum concentration of serotonin and dopamine after intervention, (vi) Changes in
150 physical and psychological parameters. Each participant was requested to answer the
151 designed questionnaire for the assessment of physical, behavioral and psychological
152 parameters as per the Hopkins Symptom Checklist (HSCL): A self-report symptom
153 inventory^{29, 30}. This questionnaire was prepared to evaluate several physical parameters
154 including muscle stiffness, heartburn, headache, shakiness, sleep problem, difficulty in
155 completing work, procrastination, overwhelming, feeling of depression, trouble relaxing,
156 nervousness, poor concentration, restlessness and quick temper. All the symptoms and
157 parameters were evaluated based on scores, the decrease in the score indicating the
158 reduction in the severity of symptoms and increase in the score indicating an augmentation
159 in the severity of the symptom.

160 ■ **Safety evaluation:** Safety of investigational product was assessed by adverse event
161 reporting. During hospital visit of the patient physical examination, monitoring of vital
162 signs and routine laboratory investigations.

- 163 ▪ **Sample collection and processing:** A stool sample and a blood sample were collected
164 from each enrolled subject before and after intervention. A fresh stool sample was
165 collected in a sterile container and a blood sample in a plain vial was collected from each
166 enrolled subject. After collection, the stool samples were aliquoted and processed for
167 microbial identification and bacterial DNA isolation. Blood samples were processed for
168 serum separation by centrifuging at 3000-4000 rpm for 5-10 min. The serum samples
169 were used for cytokine assays, serotonin and dopamine concentration.
- 170 ▪ **Microbial culture and identification:** *Bacillus coagulans* Unique IS2, and *Lactobacillus*
171 *spp.* were checked in each patient before and after intervention using different bacterial
172 media. Mueller Hinton (MH) broth and agar (Difco Laboratory, Detroit, MI) was used for
173 the cultivation of *Bacillus* strains. The stool sample were incubated for 24 hours at 37°C in
174 MH broth and then plated on MH agar plate. Simultaneously Chrome *Bacillus* agar (Hi
175 Media) was also used to isolate the *Bacillus coagulans* Unique IS2 after 24 hours at 30°C
176 incubation. The isolated colonies were identified by standard microbial identification
177 methods (conventional culture and biochemical method), matrix-assisted laser desorption
178 /ionization- (MALDI-and the mass analyzer is time-of-flight (TOF) analyzer
179 (bioMérieuxInc, USA) and molecular method. de Man, Rogosa and Sharpe (MRS) broth
180 and agar (Difco Laboratory, Detroit, MI) was used to grow *Lactobacillus*. The stool
181 sample were incubated for 48 hours at 37°C in MRS broth in Anaerobic Glove Box
182 (Anaerobic Workstation-Whitley DG250-DonWhitley Scientific, United Kingdom) in
183 anaerobic condition and then plated on MRS agar plate.
- 184 ▪ **Molecular identification of Bacteria:** *B. coagulans* was identified via 16S rRNA
185 sequencing using direct PCR with the published primers: forward 5'-
186 ACAGGGCTTTCAGATACCCG-3' and reverse 5'-CGGGGATCCGTCCATCAAAA-3'.
187 Sequence similarity was checked using BLAST, NCBI and it was 96% identical. Primers
188 were standardized at different temperatures using 54 °C, 55 °C and 56 °C degrees for
189 PCR. A known strain of *B. coagulans* Unique IS2 was procured from manufacturer and
190 used as a positive control. The reaction mixture consisted of 0.5ul of dNTP (10mM), 0.5ul
191 of DNA template (177ng/ul), 2.5 ul of reaction buffer (10X) with MgCL₂, 0.5ul of each of
192 primers (pm/ul), 0.5ul of 5U/ulTaq DNA polymerase (Thermo scientific, USA) and 20 µl
193 of nuclease free H₂O. Denaturation was done at 94 °C for 5min, followed by 30 cycles
194 consisting of 94°C for 1 min, 56°C for 1 min, and 72°C for 1 min which has been ended
195 by a final amplification step at 72 °C for 8min, using the PCR machine (Applied

196 Biosystems, USA). PCR product was analyzed by the electrophoresis in 1% agarose gel
197 and gel bands were observed and recorded using via Gel Doc System (BioRad, USA).

198

199 **Next generation sequencing (NGS) of Gut microbiota-**

200 ■ **Fecal samples collection and DNA isolation:** Fecal sample were collected in sterile
201 container and samples were processed for DNA isolation. Total DNA was extracted by
202 using QIAamp DNA Stool Mini Kit (Qiagen) with some modification to increase DNA
203 yield. The quality and quantity of DNA was checked by Nanodrop (TECAN Nano quant).
204 16S rRNA amplicon sequencing was performed using Illumina MiSeq® sequencing
205 system (Illumina, San Diego, CA, USA).

206 ■ **Sequencing Methodology:** Bacterial 16S rRNA hyper variable regions V3-V4 were
207 amplified using V3-V4F (CCTACGGGNGGCWGCAG) and V3-V4R
208 (GACTACHVGGGTATCTAATCC) primers. 25ng of DNA was used for PCR
209 amplification using KAPA HiFi HotStart Ready Mix. The PCR was performed with
210 standard protocol and the amplicons were purified using Ampure beads to remove unused
211 primers. The amplicon product was PCR amplified with Illumina primers to generate
212 sequencing libraries followed by Ampure bead cleanup. Qubit dsDNA High Sensitivity
213 assay kit was used for Libraries preparation. Sequencing was done using Illumina Miseq
214 with 2x300PE V3 sequencing kit. The sequence data quality was checked using FastQC
215 and MultiQC software. All the samples have passed QC threshold (Q30>80%).

216 ■ **Data Analysis:** The analysis was done as per standard methodology³¹. Only QC passed
217 reads were transferred into mothur and the pairs were aligned. The contigs were screened
218 for errors and ambiguous once were rejected and duplicates were merged. High quality
219 contigs were used. Chimeric sequences were identified by a known reference and
220 UCHIME algorithm was used. Using Silva v.132 database final filtered contigs were
221 classified into taxonomical outlines and clustered into Operational Taxonomic Unit
222 (OTUs) and abundance was calculated. Alpha diversity was assessed for richness and
223 relative abundance of bacteria. Alpha diversity indices Chao1 and ACE were used for
224 richness and Shannon, Simpson, InvSimpson and Fisher were used for both richness and
225 relative abundance. Kruskal-Wallis rank sum test was carried out to identify statistically
226 significant difference among OTUs abundance between groups.

227


228 ▪ **ELISA for Cytokines, serum serotonin and dopamine:**

229 Serum samples were tested and quantified for different cytokines including IL10, IL6,
230 IL17, IL23, IL 1 β , TNF, serum serotonin and dopamine as per standard protocol and
231 manufacture's instruction (Fine Test, Fine Biotech Co. Ltd). In brief, pre-coated 96 well
232 plates were used. Provided standards, test samples were added to wells and incubated at
233 37C for 90 min. After incubation, wells were washed twice with the freshly prepared wash
234 buffer and secondary antibody were added into each well and incubated at 37C for 60 min.
235 Further, wells were washed twice and HRP-Streptavidin was added and incubated at 37C
236 for 30 min. Multiple washing was done with the wash buffer to wash unbound conjugates.
237 TMB substrates were used to visualize HRP enzymatic reaction. Absorbance at 450 nm
238 has been measured using the microplate reader (Nanodrop, Nanoquant Infinite M 200 Pro
239 (Texan, Austria GmbH) and the concentration were calculated.

240 **Data analysis:** Here we have reported the analysis of data of the patients of ulcerative
241 colitis (UC). Data from 48 subjects in treatment group and 49 subjects in placebo group
242 were analysed. Statistical analysis was done by STATA statistical software (Version 14,
243 USA). Statistical evaluation of parameters was assessed by Chi-square/two sample *t*-test
244 and p value < 0.05 was considered as statistically significant.

245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279

'CONSORT' Flow Chart



Results

280
281
282

Survival of *Bacillus coagulans* Unique IS2 in the gut

283 The samples of the enrolled subjects in the both treatment and placebo group were
284 assessed for the presence of *Bacillus coagulans* Unique IS-2 before and after treatment. No
285 *Bacillus coagulans* was detected in pre-treatment sample in both the groups. In the probiotic
286 treated group *Bacillus coagulans* was detected in 65.21 % subjects by microbial culture
287 method and 76.08 % subjects by molecular method which was significant as compared to
288 placebo ($p < 0.0001$). The samples from the subjects of placebo group were also assessed for
289 the presence of *Bacillus coagulans* with no *Bacillus coagulans* being detected in placebo
290 group by both microbial and molecular methods. These results indicate that the probiotic
291 strain *Bacillus coagulans* Unique IS-2 was able to survive in GI tract of recruited IBD
292 patients.

293
294

Detection of beneficial *Lactobacilli* by microbial culture method

295 The samples of the enrolled IBD patients in both probiotic treated group and placebo
296 group were assessed for the presence of beneficial *Lactobacilli*, before and after intervention
297 by microbial culture method. Results revealed that in the probiotic treated group, beneficial
298 *Lactobacilli* were detected in 54.34 % and 78.26 % patients before and after intervention
299 respectively. In the placebo group beneficial *Lactobacilli* were detected in 52.08 % and
300 47.91 % of patients before and after intervention respectively. The detection of beneficial
301 *Lactobacilli* after intervention in the probiotic treated group was significantly high ($p < 0.01$)
302 which indicated that the probiotic strain *Bacillus coagulans* Unique IS-2 was able to enhance
303 the presence of beneficial *Lactobacilli* in recruited IBD patients.

304

Next generation Sequencing (NGS) and Metagenomic analysis of gut microbiota


305 **Phyla:** Operational Taxonomic Unit (OTUs) were calculated for different bacterial taxon
306 including phyla, class, orders, families, genera and species before and after intervention in
307 both probiotic treated and placebo group. Analysis revealed Phylum Firmicutes
308 Bacteroidetes, Proteobacteria, Actinobacteria, Euryarchaeota and Verrucomicrobia were
309 abundant in both the groups. The average % OTUs of phylum *Firmicutes* were in 33.13%
310 and 36.23% in pre and post intervention sample respectively in treatment group and 37.90%
311 and 42.89% in placebo group. The average % OTUs of phylum *Bacteroidetes* were in
312 40.12% and 40.28% in pre and post intervention sample respectively in treatment group and
313 32.49% and 40.28% in pre and post intervention sample respectively in placebo group.

314

315 OTUs of phylum *Bacteroidetes* were significantly increased in post intervention sample in
316 placebo group. The average % OTUs of phylum *Proteobacteria* were in 12.90% and 7.50%
317 in pre and post intervention sample respectively in treatment group and 16.75% and 6.21% in
318 placebo group. The average % OTUs of phylum *Actinobacteria* were in 6.64% and 4.29% in
319 pre and post intervention sample respectively in treatment group and 8.62% and 2.04% in
320 placebo group. Decrease in OTUs of phylum *Proteobacteria* and phylum *Actinobacteria*
321 was significant in the treatment group. The average % OTUs of phylum *Euryarchaeota* were
322 in 1.02% and 2.36% in pre and post intervention sample respectively in treatment group and
323 2.03% and 0.55% in placebo group. OTUs of phylum *Euryarchaeota* were increased in post
324 intervention sample in treatment group and decreased in placebo group. The average %
325 OTUs of phylum *Verrucomicrobia* were in 0.01% and 0.04% in pre and post intervention
326 sample respectively in treatment group and 0.96% and 0.10% in placebo group. OTUs of
327 phylum *Verrucomicrobia* were increased in post intervention sample in treatment group and
328 decreased in placebo group. The other bacterial phyla detected were *Lentisphaerae*,
329 *Patescibacteria*, *Acidobacteria*, *Chloroflexi*, *Epsilonbacteraeota*, *Parabasalia*, *Cynobacteria*,
330 *Fusobacteria*, *Gemmatimonadetes*, *Synergistetes*, *Tenericutes* and the OTUs of these bacterial
331 phyla were low in both groups.

332

333 **Figure 1: Abundance of major bacterial phyla**




334

335 **Class:** The average % OTUs of class Bacteroidia were 40.11% and 40.27% in pre and post
336 intervention sample respectively in treatment group and 32.48% and 43.63% pre and post
337 intervention sample respectively in placebo group. An increase in OTUs of class Bacteroidia
338 was significant in the placebo group. The average % OTUs of class Clostridia were 15.20%
339 and 22.09% in pre and post intervention sample respectively in treatment group and 20.79%
340 and 28.82% pre and post intervention sample respectively in placebo group. Increase in
341 OTUs of class Clostridia in post intervention samples was observed in both treatment and
342 placebo group. The average % OTUs of class Gammaproteobacteria were 12.87 % and
343 7.41% in pre and post intervention sample respectively in treatment group and 16.72% and
344 6.16% respectively in placebo group. A decrease in OTUs of class Gammaproteobacteria in
345 post intervention samples was observed in both treatment and placebo group. The average %
346 OTUs of class Negativicutes were 7.96% and 6.35% in pre and post intervention sample
347 respectively in treatment group and 3.49% and 7.22% respectively in placebo group. A
348 decrease was observed in OTUs of class Negativicutes in post intervention samples of
349 treatment group and an increase in post intervention samples in placebo group. The average

350 % OTUs of class Methanobacteria were 1.02% and 2.36% in pre and post intervention
 351 sample respectively in treatment group and 2.03% and 0.55% in placebo group. An increase
 352 in OTUs of class Methanobacteria in post intervention samples was observed in treatment
 353 group and decrease in OTUs of class Methanobacteria in placebo group. The average %
 354 OTUs of class Actinobacteria were 3.49% and 1.81% in pre and post intervention sample
 355 respectively in treatment group and 7.76% and 1.64% pre and post intervention sample
 356 respectively in placebo group. A decrease in OTUs of class Actinobacteria was observed in
 357 post intervention samples in both treatment and placebo group.


358 **Figure 2: Abundance of major bacterial classes**



359 **Order:** The average % OTUs of order Bacteroidales were 39.94% and 40.03% in pre and
 360 post intervention sample respectively in treatment group and 32.37% and 43.46% in placebo
 361 group. A significant increase in OTUs of order Bacteroidales in post intervention samples
 362 was observed in placebo group. The average % OTUs of order Clostridiales was 15.19%
 363 and 22.08% in pre and post intervention sample respectively in treatment group and 20.79%
 364 and 28.81% in placebo group. An increase in OTUs of order Clostridiales in post
 365

366 intervention samples was observed in both treatment and placebo group. The average %
 367 OTUs of order Selenomonadales was 8.02% and 6.30 % in pre and post intervention sample
 368 respectively in treatment group and 3.49% and 7.22% in placebo group. A decrease in OTUs
 369 of order Selenomonadales in post intervention samples in treatment group and increase in
 370 post intervention samples in placebo group. The average % OTUs of order Lactobacillales
 371 was 1.67% and 2.49% in pre and post intervention sample respectively in treatment group
 372 and 10.66% and 3.82% in placebo group. An increase in OTUs of order Lactobacillales was
 373 observed in post intervention samples in treatment group and decrease in post intervention
 374 samples in placebo group. The average % OTUs of order Erysipelotrichales was 7.00% and
 375 5.03% in pre and post intervention sample respectively in treatment group and 2.48 % and
 376 2.48% in placebo group. A decrease in OTUs of order Erysipelotrichales in post intervention
 377 samples in treatment group and increase in placebo group were observed. The average %
 378 OTUs of order Bifidobacteriales were 1.74% and 3.55% in pre and post intervention sample
 379 respectively in treatment group and 7.71% and 1.61% respectively in placebo group. An
 380 increase in OTUs of order Bifidobacteriales in post intervention samples in treatment group
 381 and decrease in placebo group were observed.


382 **Figure 3: Abundance of major bacterial orders**



383

384 **Family:** The average % OTUs of family Prevotellaceae was 32.66% and 33.20% in pre and
385 post intervention sample respectively in treatment group and 8.62% and 31.96% in placebo
386 group. Significant increase was observed in OTUs of family Prevotellaceae in post
387 intervention samples in placebo group. The average % OTUs of family Ruminococcaceae
388 was 8.22% and 11.99% in pre and post intervention sample respectively in treatment group
389 and 12.34% and 12.23% in placebo group. Increase in OTUs of family Ruminococcaceae in
390 post intervention samples in treatment group and decrease in placebo group. The average %
391 OTUs of family Bacteroidaceae was 4.09% and 4.58 % in pre and post intervention sample
392 respectively in treatment group 22.85% and 9.44% in placebo group. Increase in OTUs of
393 family Bacteroidaceae in post intervention samples in treatment group and decrease in
394 placebo group were observed. The average % OTUs of family Lachnospiraceae was 6.14 %
395 and 8.40 % in pre and post intervention sample respectively in treatment group and 6.79 %
396 and 13.48 % respectively in placebo group. Increase in OTUs of family Lachnospiraceae in
397 post intervention samples in both treatment and placebo group. The average % OTUs of
398 family Veillonellaceae was 7.47% and 5.72 % in pre and post intervention sample
399 respectively in treatment group and 3.49 % and 7.15% in placebo group. Decrease in OTUs
400 of family Veillonellaceae in post intervention samples in treatment group and increase in
401 placebo group were observed. The average % OTUs of family Enterobacteriaceae was 4.69
402 % and 3.14 % in pre and post intervention sample respectively in treatment group and 9.79%
403 and 2.41 % respectively in placebo group. A significant decrease was observed in OTUs of
404 family Enterobacteriaceae in post intervention samples in placebo group. The average %
405 OTUs of family Lactobacillaceae was 1.12% and 2.03% in pre and post intervention sample
406 respectively in treatment group and 6.36 % and 3.22 % respectively in placebo group.
407 Increase in OTUs of family Lactobacillaceae in post intervention samples in treatment group
408 and decrease in placebo group were observed. The average % OTUs of family
409 Bifidobacteriaceae was 1.74% and 3.55% in pre and post intervention sample respectively in
410 treatment group and 7.71% and 1.61% respectively in placebo group. Increase in OTUs of
411 family Bifidobacteriaceae in post intervention samples in treatment group and decrease in
412 placebo group were observed.

413 **Figure 4: Abundance of major bacterial families**



414

415


416 **Genera:** The average % OTUs of genus *Prevotella* were 26.37% and 22.10% in pre and post
417 intervention sample respectively in treatment group and 10.28% and 25.57% respectively in
418 placebo group. Decrease in OTUs of genus *Prevotella* in post intervention samples in
419 treatment group and an increase in placebo group was observed. The average % OTUs of
420 genus *Bacteroides* were 4.88% and 6.13% in pre and post intervention sample respectively in
421 treatment group and 19.96% and 7.89% respectively in placebo group. An increase in OTUs
422 of genus *Bacteroides* in post intervention samples in treatment group and decrease in placebo
423 group were observed. Average % OTUs of genus *Faecalibacterium* were 6.56% and 6.87%
424 in pre and post intervention sample respectively in treatment group and 9.23% and 8.01%
425 respectively in placebo group. An increase in OTUs of genus *Faecalibacterium* in post
426 intervention samples in treatment group and decrease in placebo group were observed. The
427 average % OTUs of genus *Lactobacillus* were 1.21% and 2.59% in pre and post intervention
428 sample respectively in treatment group and 7.33% and 3.49% respectively in placebo group.
429 An increase in OTUs of genus *Lactobacillus* in post intervention samples in treatment group
430 and decrease in placebo group were observed. The average % OTUs of genus

431 *Bifidobacterium* were 1.67% and 4.44% in pre and post intervention sample respectively in
432 treatment group and 6.03% and 1.42% respectively in placebo group. An increase in OTUs
433 of genus *Bifidobacterium* in post intervention samples in treatment group and decrease in
434 placebo group were observed. The average % OTUs of genus *Bacillus* were 0.01% and
435 0.04% in pre and post intervention sample respectively in treatment group and 0.001% and
436 0.001% respectively in placebo group. OTUs of Genus *Bacillus* in post intervention samples
437 in treatment group were high while OTUs of genus *Bacillus* in placebo group were very low.
438 The average % OTUs of genus *Faecalibacterium* were 6.56% and 6.87% in pre and post
439 intervention sample respectively in treatment group and 9.23% and 8.01% respectively in
440 placebo group. An increase in OTUs of genus *Faecalibacterium* in post intervention samples
441 in treatment group and decrease was observed in placebo group. The average % OTUs of
442 genus *Bacteroides* were 4.88% and 6.13% in pre and post intervention sample respectively in
443 treatment group and 19.96% and 7.89% in placebo group. An increase in OTUs of genus
444 *Bacteroides* in post intervention samples in treatment group and decrease in placebo group
445 was observed. The average % OTUs of genus *Escherichia* were 3.61% and 1.24% in pre and
446 post intervention sample respectively in treatment group and 11.06% and 1.81% in placebo
447 group. A decrease in OTUs of genus *Escherichia* was observed in post intervention samples
448 in treatment and placebo group. The average % OTUs of genus *Sutterella* were 3.05% and
449 2.22% in pre and post intervention sample respectively in treatment group and 3.60% and
450 1.68 % in placebo group. A decrease in OTUs of genus *Sutterella* was observed in post
451 intervention samples in both treatment and placebo group. The average % OTUs of genus
452 *Dialister* were 3.37% and 1.98% in pre and post intervention sample respectively in treatment
453 group and 0.09% and 3.66% respectively in placebo group. A decrease in OTUs of genus
454 *Dialister* was observed in post intervention samples in treatment group and increase in
455 placebo group. The average % OTUs of genus *Megamonas* were 1.39% and 2.17% in pre
456 and post intervention sample respectively in treatment group and 0.73% and 0.001%
457 respectively in placebo group. An increase in OTUs of genus *Megamonas* was observed in
458 post intervention samples in treatment group and decrease in placebo group. The average %
459 OTUs of genus *Roseburia* were 0.82% and 0.45% in pre and post intervention sample
460 respectively in treatment group and 1.18% and 2.46% in placebo group. A decrease in OTUs
461 of genus *Roseburia* was observed in post intervention samples in treatment group and
462 increase in placebo group. The average % OTUs of genus *Megasphaera* were 2.37% and
463 0.36% in pre and post intervention sample respectively in treatment group and 2.02% and
464 1.97% in placebo group. A decrease in OTUs of genus *Megasphaera* was observed in post

465 intervention samples in both treatment and placebo group. The average % OTUs of genus
466 *Lachnospira* were 0.42% and 0.34% in pre and post intervention sample respectively in
467 treatment group and 1.49% and 2.83% in placebo group. An increase in OTUs of genus
468 *Lachnospira* was observed in post intervention samples in treatment group and decrease in
469 placebo group. The average % OTUs of genus *Blautia* were 0.25% and 0.40% in pre and
470 post intervention sample respectively in treatment group and 0.12% and 0.25% in placebo
471 group. An increase in OTUs of genus *Blautia* was observed in post intervention samples in
472 both treatment and placebo group. The average % OTUs of genus *Alistipes* were 0.08% and
473 0.37% in pre and post intervention sample respectively in treatment group and 0.12% and
474 0.04% in placebo group. An increase in OTUs of genus *Alistipes* in post intervention
475 samples in treatment group and decrease in placebo group were observed.

476

477 **Figure 5: Abundance of major bacterial genera**



478

479 Cytokines levels

480 Serum concentrations of different cytokines were assessed before and after
481 intervention and results are expressed as Mean \pm SD. In the probiotic treated group serum
482 levels of IL10 were 3.23 ± 1.22 pg/ml and 9.25 ± 2.6 pg/ml before and after intervention
483 respectively with the difference being significant ($p < 0.05$). In the placebo group serum
484 IL10 levels were 2.47 ± 1.19 pg/ml and 2.97 ± 1.67 pg/ml before and after intervention
485 respectively, this difference was not significant ($p = ns$). Results indicated that the secretion
486 of IL-10 in IBD-UC patients was increased in *B coagulans* Unique IS2 group. In the
487 treatment group serum IL6 levels were 34.13 ± 6.8 pg/ml and 17.64 ± 5.2 pg/ml before and
488 after intervention respectively with the difference being significant ($p < 0.05$). In the placebo
489 group serum IL6 levels were 35.85 ± 7.6 pg/ml and 28.49 ± 6.4 pg/ml before and after
490 intervention respectively and this difference was not significant ($p = ns$). The observed
491 results indicated that the secretion of IL-6 in IBD-UC patients was decreased in *B coagulans*
492 Unique IS2 group. In the probiotic treated group, serum IL17 levels were 42.82 ± 6.9 pg/ml
493 and 28.57 ± 5.4 pg/ml before and after intervention respectively with the difference being
494 significant ($p < 0.05$). In the placebo group serum IL17 levels were 36.73 ± 13.73 pg/ml and
495 33.96 ± 14.74 pg/ml before and after intervention respectively with the difference not being
496 significant ($p = ns$). The observed results indicated that the secretion of serum IL-17 was
497 decreased in IBD-UC patients in the probiotic group. In the probiotic treated group serum
498 IL23 levels were 938.39 ± 56.57 pg/ml and 842.20 ± 69.43 pg/ml before and after
499 intervention respectively with the difference not being significant. In the placebo group
500 serum IL23 levels were 951.59 ± 61.31 pg/ml and 932.02 ± 43.30 pg/ml before and after
501 intervention respectively with the difference not being significant ($p = ns$).

502 In the treatment group serum IL-1 β levels were 358.58 ± 39.29 pg/ml and $267.28 \pm$
503 33.88 pg/ml before and after intervention respectively with the difference being significant (p
504 < 0.05). In the placebo group serum IL-1 β levels were 363.93 ± 35.57 pg/ml and $382.59 \pm$
505 37.50 pg/ml before and after intervention respectively with the difference not being
506 significant ($p = ns$). The observed results indicated that the secretion of serum IL-1 β in IBD-
507 UC patients was increased in *B coagulans* Unique IS2 group. In the treatment group serum
508 TNF- α levels were 80.33 ± 13.68 pg/ml and 69.16 ± 14.79 pg/ml before and after
509 intervention respectively with the difference not significant whereas in the placebo group
510 serum TNF- α levels were 76.35 ± 14.72 pg/ml and 79.39 ± 13.8 pg/ml before and after
511 intervention respectively with the difference not being significant.

512 **Serum serotonin and dopamine levels:**

513 In the treatment group serum serotonin level were 121.48 ± 15.52 ng/ml and $111.30 \pm$
 514 17.74 ng/ml before and after intervention and the difference was not significant. In the
 515 placebo group serotonin level were 118.12 ± 19.25 ng/ml and 109.88 ± 11.23 ng/ml before
 516 and after intervention and the difference was not significant. In the treatment group serum
 517 dopamine level were 8.51 ± 2.52 pg/ml and 11.74 ± 2.25 pg/ml before and after intervention
 518 and the difference was not significant. In the placebo group dopamine level were 8.48 ± 2.89
 519 pg/ml and 10.89 ± 2.99 pg/ml, before and after intervention and the difference was not
 520 significant. There were changes in serotonin and dopamine levels in the subjects before and
 521 after intervention but the difference was not significant.

522 **Table 1: Serum Cytokines, serotonin and dopamine levels in pre and post intervention**
 523 **samples in treatment and placebo group**

Cytokine (pg/ml)	<i>Bacillus coagulans</i> Unique IS2 group			Placebo group		
	Pre	Post	P value	Pre	Post	P value
IL-10	3.23 ± 1.22	9.25 ± 2.6	<0.05	2.47 ± 1.19	2.97 ± 1.67	NS
IL-6	34.13 ± 6.8	17.64 ± 5.2	<0.05	35.85 ± 7.6	28.49 ± 6.4	NS
IL-17	42.82 ± 6.9	28.57 ± 5.4	<0.05	36.73 ± 13.7	33.96 ± 14.74	NS
IL-23	938.39 ± 56.5	842.20 ± 69.4	NS	951.59 ± 61.3	932.02 ± 43.30	NS
IL-1 β	358.58 ± 39.2	267.28 ± 33.8	<0.05	363.93 ± 35.5	382.59 ± 37.50	NS
TNF- α	80.33 ± 13.6	69.16 ± 14.7	NS	76.35 ± 14.7	79.39 ± 13.8	NS
Serotonin (ng/ml)	121.48 ± 15.5	111.30 ± 17.7	NS	118.12 ± 19.2	109.88 ± 11.23	NS
Dopamine (pg/ml)	8.51 ± 2.52	11.74 ± 2.2	NS	8.48 ± 2.89	10.89 ± 2.99	NS

524

525 **Effect on disease symptoms**

526 Symptoms of disease were assessed based on patient complaint and SCCAI score was
 527 calculated for IBD-UC patients as per standard protocol. The decrease in the SCCAI score
 528 indicates the reduction in the severity of symptoms and increase in the score indicates the
 529 augmentation in the severity of the symptom of UC. In this study reduction of 1 value in
 530 SCCAI score was considered as decrease in SCCAI score. The SCCAI score was decreased
 531 post intervention in 43.75 % of the patients in the probiotic treated group which was
 532 significantly high ($p < 0.05$) as compared to placebo where the decrease in SCCAI score was
 533 reported in 28.57 % patients.

534 **Effect on physical, behavioral and psychological parameters**

535 The enrolled subjects were assessed before and after intervention for the different
536 physical symptoms, behavioral and psychological symptoms including stiff or tense muscles,
537 heartburn, headache, shakiness or tremor, sleep problem, difficulty in completing work,
538 procrastination, overwhelming, feeling of depression, trouble relaxing, nervousness, poor
539 concentration, quick temper and restlessness. All the symptoms were evaluated based on
540 scores, the decrease in the score indicates the reduction in the severity of symptoms and
541 increase in the score indicates the augmentation in the severity of the symptom. In this study
542 the complaint of muscles stiffness was reduced post intervention in 41.66 % and 29.16 %
543 subjects in the treatment and placebo group respectively and the difference between the
544 groups was significant ($p < 0.05$). The complaint of heartburn was reduced post intervention
545 in 43.75 % and 31.25 % subjects in the treatment and placebo group respectively and the
546 difference between the groups was significant ($p < 0.05$). The complaints of headache were
547 reduced post intervention in 37.5 % and 33.33 % subjects in the probiotic and placebo group
548 respectively with no significant difference between groups. The complaint of shakiness or
549 tremor was reduced post intervention in 33.33 % and 31.25 % subjects in the treatment and
550 placebo group with no significant difference between groups.

551 The complaint of sleep problem was reduced post intervention in 41.66 % and 27.08
552 % subjects in the treatment and placebo group respectively with the difference between
553 groups being significant ($p < 0.05$). The complaint of procrastination was reduced in 31.25 %
554 subjects and 35.4 % subjects in the treatment and placebo group respectively with no
555 significant difference between groups. The complaints of difficulty in completing work or
556 assignments was decreased post intervention in 37.5 % subjects and 27.08 % subjects in the
557 probiotic treated and placebo group respectively with the difference between groups being
558 significant ($p < 0.05$). The complaints of overwhelming was reduced post intervention in
559 41.66 % and 31.25 % subjects in the treatment and placebo group respectively and the
560 difference between placebo and treatment groups was significant ($p < 0.05$). The complaints
561 of trouble relaxing was reduced post intervention in 37.5 % and 27.08 % subjects in the
562 treatment group and placebo group respectively with the difference between groups being
563 significant ($p < 0.05$). The complaint of nervousness was reduced post intervention in 33.33
564 % and 29.16 % subjects in the treatment and placebo group respectively with no significant
565 difference between groups. The complaints of depression was reduced post intervention in
566 33.33 % and 31.25 % subjects in the treatment and placebo group respectively with no
567 significant difference between groups. The complaints of poor concentration was reduced

568 post intervention in 47.91 % and 33.3 % subjects in the treatment group and placebo group
 569 respectively with the difference between groups being significant ($p < 0.05$). The complaints
 570 of quick temper was reduced post intervention in 45.83 % and 39.58 % subjects in the
 571 treatment group and placebo group respectively with no significant difference. The
 572 complaints of restlessness was reduced post intervention in 47.91 % and 35.4 % subjects in
 573 the treatment group and placebo group respectively with the difference between groups being
 574 significant ($p < 0.05$). The observed results exhibited improvement in various physical,
 575 behavioral and psychological symptoms of enrolled IBD subjects in the treatment group.

576 **Table 2: Post intervention decrease in symptoms in the enrolled subjects for different**
 577 **physical, behavioral and psychological parameters**

578

Physical, behavioural and psychological parameters	Post intervention decrease in symptoms (% of total subjects)		
	<i>Bacillus coagulans</i> Unique IS2 group	Placebo group	P value
Muscles stiffness	41.66 %	29.16 %	<0.05
Heartburn	43.75	31.25 %	<0.05
Headache	37.5 %	33.33 %	NS
Shakiness or tremor	33.33 %	31.25 %	NS
Sleep problem	41.66 %	27.08 %	<0.05
Procrastination	31.25 %	35.4 %	NS
Difficulty in completing work or assignments	37.5 %	27.08 %	<0.05
Overwhelming	41.66 %	31.25 %	<0.05
Trouble relaxing	37.5 %	27.08 %	<0.05
Nervousness	33.33 %	29.16 %	NS
Depression	33.33 %	31.25 %	NS
Poor concentration	47.91 %	33.3 %	<0.05
Quick temper	45.83 %	39.58 %	NS
Restlessness	47.91 %	35.4 %	<0.05

579

580 **Safety evaluations:** During and after intervention no adverse events were observed, recorded
 581 and reported in the study which further established the safety of *B coagulans* Unique IS2.

Discussion

582

583

584

585

586

587

588

589

590

591

592

593

Targeted microbiota intervention through probiotics and fecal microbiota transplantation are considered as effective therapeutic methods for IBD^{12, 32}. Mechanisms of action of probiotics in IBD prevention include, increase in beneficial bacteria, inhibition of pathogenic bacteria, immuno-modulation, augmentation of anti-inflammatory responses and enhancement of the intestinal barrier function¹⁴. Studies have demonstrated that probiotics play an important role in human health and that enhance the interest of researchers in the preventive and therapeutic applications of probiotics³³. Probiotic effects are strain specific therefore the efficacy of each probiotic strain needs to be evaluated and studies with different probiotic agents are necessary to identify safe and effective probiotic with therapeutic potential for IBD.

594

595

596

597

598

599

600

601

602

603

604

605

Bacillus species are spores forming due to which they have high heat resistance, acid tolerance and they can survive considerably better than other probiotics in gastric conditions^(34, 35). *B. coagulans* Unique IS2 is a non-toxic commercial probiotic strain with proven safety and efficacy, long shelf life and stability at room temperature²⁴. Whole genome sequence analysis of *B. coagulans* Unique IS-2 has corroborated its safety with the absence of any toxin genes⁽³⁴⁾. In this study, no severe adverse event was detected, which establish the safety of *B. coagulans* Unique IS-2. Safety and therapeutic efficacy of *B. coagulans* Unique IS2 has been proven through various clinical trials on different disease including Irritable bowel syndrome in adult²⁷ and children²⁵, acute-diarrhea²³, abdominal pain³⁵, constipation²⁷, bacterial vaginosis²⁶, anti-hypercholesterolemic effect²² and liver cirrhosis³⁶. Anti-inflammatory and anti-proliferative effects activity also strengthened the therapeutic applicability of the strain³⁷ and in colon cancer cells³⁸.

606

607

608

609

610

611

612

613

614

615

Post intervention, significant detection of *Bacillus coagulans* in the probiotic treated group demonstrating that this probiotic strain was able to survive in GI tract of IBD patients. Studies have reported that beneficial bacteria provide protection to host against colonization of harmful bacteria and suppress the growth of pathogens by imposing competition for shared niches and nutrients³⁹. Results of the present study indicated that *B. coagulans* Unique IS-2 was able to modulate the gut microbiota by increasing beneficial bacteria. Another study also reported that consumption of *B. coagulans* was capable of restoring the microbial imbalance⁴⁰ and able to increase populations of *Lactobacillus* and *Bifidobacteria*^{41, 33} possibly by consuming free oxygen in the intestine and reduces redox reactions, creating an unfavorable anaerobic and acidic environment to various pathogens³³.

616 The gut bacterial diversity was also assessed by Next Generation Sequencing and
617 metagenomics in both the groups. Results of the study revealed that phylum Firmicutes,
618 Bacteroidetes, Proteobacteria, Actinobacteria, Euryarchaeota and Verrucomicrobia were
619 abundant in both the study group. Other studies have also reported that Indian gut
620 microbiome is dominated by these bacterial phyla including Firmicutes, Bacteroidetes,
621 Actinobacteria and Proteobacteria^{42, 43}. An increase in the abundance of phylum Firmicutes
622 and phylum Bacteroidetes was observed in post intervention sample in both groups.
623 Decrease in abundance of phylum Proteobacteria and phylum Actinobacteria was observed in
624 post intervention sample in both groups. Other studies also reported that the decrease of
625 Bacteroides and Firmicutes and increase of Proteobacteria and Actinobacteria in GI disease
626^{44, 45}. It is believed that inflammation is an oxidative state which might promote the
627 outgrowth of aerotolerant taxa such as Proteobacteria and Actinobacteria⁴⁶. The abundance
628 of phylum Euryarchaeota and Verrucomicrobia were increased in post intervention sample in
629 treatment group and decrease in placebo group. Other studies reported the differences in the
630 gut microbiota composition, diversity and the relative abundance of specific bacterial taxa
631 between IBD patients and healthy individuals⁴⁶.

632 The abundance of *Lactobacillus*, *Bifidobacterium* and *Bacillus* genera was increased
633 in post intervention samples in treatment group and decrease in placebo group. Lactic acid
634 bacteria and *Bifidobacteria* are among the first colonizers of newborns⁴⁷ and are known for
635 their beneficial effects⁴⁸. The observed high abundance of *Lactobacillus*, *Bifidobacterium*
636 and *Bacillus* genera in treatment group indicated that given probiotic help the gut in restoring
637 these beneficial bacteria. Studies reported decreased abundance of *Faecalibacterium* in IBD
638^{49, 50}. We observed an increase in abundance of genus *Faecalibacterium* in post intervention
639 samples in treatment group and decrease in placebo group which indicates the given probiotic
640 help the gut in restoring them. Bacterial genera *Lactobacillus*, *Bifidobacterium*, and
641 *Faecalibacterium* have been reported to be protective for mucosal inflammation in the host¹¹,
642⁵¹ via several mechanisms, including the up-regulation of the anti-inflammatory cytokine, and
643 down-regulation of inflammatory cytokines⁵². Studies reported decrease in the genera
644 Bacteroides in IBD^{53 14}. We observed an increase in abundance of genus *Bacteroides* in post
645 intervention samples in treatment group and decrease in placebo group which indicates that
646 the given probiotic intervention may help to restore the genus *Bacteroides* in enrolled IBD
647 patients. A decrease in the abundance of bacterial genera *Escherichia* and *Sutterella* was
648 observed in post intervention samples in both treatment and placebo group. A decrease in the
649 abundance of bacterial genera *Dialister*, *Roseburia*, *Megasphaera* was observed in post

650 intervention samples in treatment group and increase in placebo group. A decrease in the
651 abundance of *Blautia* species in the IBD patients was reported⁵⁴. We observed an increase in
652 OTUs of genus *Blautia* in post intervention samples in both treatment and placebo group. An
653 increase in abundance of genus *Alistipes* in post intervention samples in treatment group and
654 decrease in placebo group were observed. Gut microbiota study in the IBD patients reported
655 that some of the Faecalibacterium *Bacteroides* and *Alistipes* species have shown significant
656 contribution to metabolic pathway transcription⁵⁵. The abundance of some of bacterial taxon
657 was low but these may play important role in gut function as reported earlier⁵⁶.

658 The improper host immune response against GI microbiota is considered to be the
659 main reason in causing severe inflammation³³. Studies have reported the changes in the
660 serum levels of anti-inflammatory cytokine (IL-10) and pro-inflammatory cytokines (IL-6,
661 IL-12, TNF- α , INF- γ) in GI disorders⁵⁷. However, the serum cytokine profiling of IBD
662 patients remains less reported. In the present study significant increase was observed in IL-
663 10 levels in treatment group which indicated that the probiotic strain was able to increase the
664 secretion of IL-10 in IBD patients in the treatment group. Studies have reported the
665 association of IBD patients with anti-inflammatory cytokines IL-10⁵⁸ and IL-10 secretion
666 increased during disease recovery in IBD patients⁵⁹. It is also reported that inactivation of
667 IL-10 leads to increased release of pro-inflammatory cytokines⁶⁰.

668 In the present study we observed the significant decrease in IL6 ($p < 0.05$), IL17 (p
669 < 0.05), IL23 ($p < 0.05$), and IL-1 β ($p < 0.05$), TNF- α in treatment group which indicated the
670 probiotic intervention was able to modulate the secretion of pro-inflammatory cytokines.
671 Previous studies have reported that the expression of IL-6 was predominantly detected in
672 IBD. Increased expression of IL-6 may be an intestinal inflammatory mediator of IBD⁶⁴. IL-
673 17 induces the production of many other pro-inflammatory factors, including TNF- α , IL-6,
674 and IL-1 β , resulting in localizing and amplifying inflammation. Studies have reported that the
675 expression of IL-6 was predominantly detected in IBD and an association between serum
676 levels of IL-6 and disease activity⁶¹. A study reported IL6 in active UC 26 +/- 10 pg/ml and
677 in inactive UC < 10 pg/ml⁶² and this suggested that increased expression of IL-6 may be an
678 intestinal inflammatory mediator of IBD. IL-17 induces the production of many other pro-
679 inflammatory cytokines, including IL-6, TNF- α , and IL-1 β , which leads to localizing and
680 amplifying inflammation. IL-17 was reported to be increased in intestinal tissue and serum of
681 IBD patients^{63, 64}. IL-1 β is a pro-inflammatory cytokines play important role in the
682 inflammation in patients with IBD and an elevation in IL-1 β levels are associated with
683 increased disease severity^{65, 66, 67}. Studies reported that the improper level of serotonin and

684 dopamine increases the severity of IBD ⁶⁸. Serum serotonin and dopamine were also
685 evaluated in the enrolled patients before and after intervention and no significant change was
686 observed in both groups.

687 Results of the study indicated that *B coagulans* Unique IS2 along with SMT was able
688 to reduce the severity of symptom and improve physical and psychological parameters in
689 IBD patient in the treatment group. These results are similar to another study which reported
690 that a probiotic mixture (VSL#3) reduced the expression of inflammatory cytokines and the
691 severity of disease in UC patients ⁶⁹. Few studies have reported the efficacy of probiotics for
692 the treatment of IBD. A meta-analysis also reported that probiotics can benefit IBD
693 treatment during combined use of probiotics and standard therapy ⁷⁰. A study with *B.*
694 *coagulans* Unique IS2 in children with functional abdominal pain indicated reduction of
695 abdominal pain in the probiotic treated group ³⁵. Another study reported *B. coagulans*
696 Unique IS2 was effective in the treatment of IBS with a significant decrease in the intensity
697 of pain in the probiotic treated group ²⁵. Probiotics can reduce inflammation and disease
698 symptoms by modulation of the mucosal immune system, increased intestinal barrier
699 function, competitive prohibition of pathogens, production of antimicrobial factors ⁷¹
700 amplification of the intestinal tight junctions to stabilize the permeability, normalize bowel
701 movements and reduce visceral hypersensitivity ^{72, 73, 74}.

702 **Summary and Conclusion**

703 The results of the study showed that the *B coagulans* Unique IS-2 is able to survive in
704 GI tract of IBD patients. *B. coagulans* Unique IS-2 was able to enhance bacterial genera
705 *Lactobacillus*, *Bifidobacterium*, *Faecalibacterium*, *Bacteroides*, *Megamonas*, *Lachnospira*,
706 *Blautia* and *Alistipes* in post intervention samples in the treatment group. A decrease in
707 bacterial genera *Sutterella*, *Dialister*, *Roseburia* and *Megasphaera* was observed in post
708 intervention samples in the treatment group. Variable alterations were also observed in the
709 abundance of different bacterial taxon including phylum, class, order, family, and genus in
710 the post intervention sample of the treatment group. *B coagulans* Unique IS-2 was able to
711 modulate the secretion of serum cytokines in IBD patients. The level of IL-10 was increased
712 significantly post intervention in treatment group. The secretion of cytokines, IL-6, IL-1 β ,
713 TNF- α , IL -17 and IL -23 were variably decreased post intervention in the treatment group.
714 No significant change in serum serotonin and dopamine was observed in both treatment and
715 placebo groups. A reduction in the severity of symptoms of disease and significant
716 improvement in the physical and psychological parameter were observed post intervention in
717 enrolled subjects in the treatment group. Observed results demonstrated that *B coagulans*
718 Unique IS2 showed beneficial effect in IBD-UC patients when administered along with
719 standard medical treatment (SMT).

720
721 **Conflict of interest statement:** RSM and JN are employed by manufacturer of probiotics
722 (Unique Biotech Ltd) and they wish to state that the study was conducted independently with
723 no intervention on their part during the study. All other authors declare no conflict of interest.

724
725 **Author Contribution:** VDB- Recruited the subjects, carried out experiments, analyzed data
726 and wrote final manuscript, DD - carried out experiments and analyzed the data, PS - carried
727 out experiments and analyzed the data. SK clinical assessment and monitoring of subjects,
728 RSM, JN – drafted study proposal and manuscript, VA- clinical assessment and monitoring
729 of subjects, designed the trial, supervised the study. RC -conceptualizes the study, finalized
730 study proposal, designed the trial and supervised the study. All the authors read and revised
731 the manuscript and approve the final manuscript.

732
733 **Acknowledgement:** Authors acknowledge the financial support from Unique Biotech Ltd,
734 Hyderabad, India. Help of Mr. Surender Singh (Laboratory Technician) in microbial culture
735 media and reagent preparation is also acknowledged.

736 References

- 737
- 738 1. Acharyya Bhaswati C, Acharyya Saumyabrata, Chakrabarty Hema. Incidence of
739 Inflammatory Bowel Disease in a Tertiary Centre of Eastern India. *Adv Res*
740 *GastroenteroHepatol* 2018; 9(5): 555774. DOI: [10.19080/ARGH.2018.09.555774](https://doi.org/10.19080/ARGH.2018.09.555774)
- 741 2. Kedia Saurabh & Ahuja Vineet (2018); Is the emergence of inflammatory bowel disease a
742 prime example of the third epidemiological transition? *Indian J of Gastroenterology*
743 37(3):183–185 <https://doi.org/10.1007/s12664-018-0852>
- 744 3. Singh P, Ananthakrishnan A, Ahuja V: Pivot to Asia: inflammatory bowel disease
745 burden. *Intest Res* 2017; 15: 138–141.
- 746 4. Kedia S and Ahuja V (2017). Epidemiology of inflammatory bowel disease in India: the
747 great shift east. *InflammIntest Dis* 2017;2:102–115 DOI: [10.1159/000465522](https://doi.org/10.1159/000465522)
- 748 5. Kim Young Sun, Jung Sung-Ae, Lee Kang-Moon, Park Soo Jung, Kim Tae Oh, Cho
749 Chang Hwan et al (2017) ; Impact of inflammatory bowel disease on daily life: an online
750 survey by the Korean Association for the Study of Intestinal Diseases; *Intest Res*
751 2017;15(3):338-344;<https://doi.org/10.5217/ir.2017.15.3.338>
- 752 6. Ko Joshua K and Auyeung Kathy K : Inflammatory Bowel Disease: Etiology,
753 Pathogenesis and Current Therapy: *Current Pharma Design*, 2014, 20, 1082-1096
- 754 7. Sigall-Boneh R, Levine A, Lomer M, et al. Research gaps in diet and nutrition in
755 inflammatory bowel disease. A topical review by D-ECCO working group [dietitians of
756 ECCO]. *J Crohns Colitis*. 2017; 11:1407–19.
- 757 8. Maunder, Robert G., and Susan Levenstein. "The role of stress in the development and
758 clinical course of inflammatory bowel disease: epidemiological evidence." *Current*
759 *molecular medicine* 8, no. 4 (2008): 247-252.
- 760 9. Kim Duk Hwan and Cheon Jae Hee (2017); Pathogenesis of Inflammatory Bowel
761 Disease and Recent Advances in Biologic Therapies: *Immune Network*: pISSN 1598-
762 2629 · eISSN 2092-6685: <https://doi.org/10.4110/in.2017.17.1.25>
- 763 10. Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A; Gut microbiota in the
764 pathogenesis of inflammatory bowel disease; *Clinical Journal of Gastroenterology*
765 (2018) 11:1–10; <https://doi.org/10.1007/s12328-017-0813-5>
- 766 11. Zuo T and Ng SC (2018): The Gut Microbiota in the Pathogenesis and Therapeutics of
767 Inflammatory Bowel Disease. *Front. Microbiol.* 9:2247.doi: [10.3389/fmicb.2018.02247](https://doi.org/10.3389/fmicb.2018.02247)
- 768 12. Dong Li-Na, Wang Mu, GuoJian, Wang Jun-Ping; Role of intestinal microbiota and
769 metabolites in inflammatory bowel disease; *Chinese Medical Journal* 2019;132(13);
770 DOI:10.1097/CM9.0000000000000290
- 771 13. Sun Yang, Li Lianwei , Xia Yao , Li Wendy , Wang Kunhua , Wang Lan, Yinglei Miao
772 & Sam Ma; The gut microbiota heterogeneity and assembly changes associated with the
773 IBD; *Scientific Reports (2019) 9:440* | DOI:10.1038/s41598-018-37143-z
- 774 14. Khan Israr, UllahNaeem, ZhaLajia, BaiYanrui, Khan Ashiq, Zhao Tang, CheTuanjie and
775 Zhang Chunjiang (2019); Alteration of Gut Microbiota in Inflammatory Bowel Disease
776 (IBD): Cause or Consequence? *IBD Treatment Targeting the Gut Microbiome*;
777 *Pathogens* 2019, 8, 126; doi: [10.3390/pathogens8030126](https://doi.org/10.3390/pathogens8030126)

- 778 15. Manocha, Marcus, and Waliul I. Khan. "Serotonin and GI disorders: an update on
779 clinical and experimental studies." *Clinical and translational gastroenterology* 3, no. 4
780 (2012): e13.
- 781 16. O'Mahony, Siobhain M., Gerard Clarke, Y. E. Borre, T. G. Dinan, and J. F. Cryan.
782 "Serotonin, tryptophan metabolism and the brain-gut-microbiome axis." *Behavioural*
783 *brain research* 277 (2015): 32-48.
- 784 17. Tolstanova, G., Deng, X., Ahluwalia, A., Paunovic, B., Prysiazniuk, A., Ostapchenko,
785 L., Szabo, S. (2015). Role of Dopamine and D2 Dopamine Receptor in the Pathogenesis
786 of Inflammatory Bowel Disease. *Digestive Diseases and Sciences*, 60(10), 2963–
787 2975. doi:10.1007/s10620-015-3698-5
- 788 18. Rhee, Sang H., Charalabos Pothoulakis, and Emeran A. Mayer. "Principles and clinical
789 implications of the brain–gut–enteric microbiota axis." *Nature reviews Gastroenterology*
790 *& hepatology* 6, no. 5 (2009): 306.
- 791 19. Reber, S. O. "Stress and animal models of inflammatory bowel disease—an update on
792 the role of the hypothalamo–pituitary–adrenal axis." *Psychoneuroendocrinology* 37, no.
793 1 (2012): 1-19.
- 794 20. Sudha, R. *et al.* Molecular typing and probiotic attributes of a new strain of *B coagulans*
795 Unique IS-2: a potential biotherapeutic agent. *Genet. Eng. Biotechnol. J.* 7, 1–20 (2010).
- 796 21. Konuray Gözde and Erginkaya Zerrin; Potential Use of *Bacillus coagulans* in the Food
797 Industry; *Foods* 2018, 7, 92; doi:10.3390/foods7060092
- 798 22. Sudha M. R., Radkar N. & Maurya, A. Effect of supplementation of probiotic *Bacillus*
799 *coagulans* Unique IS-2 (ATCC PAT-11748) on hypercholesterolemic subjects: a clinical
800 study. *Int. J. Probiotics Prebiotics* 6, 89–93 (2011).
- 801 23. Sudha, R. M. & Bhonagiri, S. Efficacy of *Bacillus coagulans* strain Unique IS-2 in the
802 treatment of patients with acute diarrhea. *Int. J. Probiotics Prebiotics* 7, 33–37 (2012).
- 803 24. Sudha, R. M., Sunita, M. & Sekhar, B. M. Safety studies of *Bacillus coagulans* Unique IS-
804 2 in rats: morphological, biochemical and clinical evaluations. *Int. J. Probiotics*
805 *Prebiotics* 11, 43–48 (2016).
- 806 25. Sudha, M. R. *et al.* Efficacy of *Bacillus coagulans* Unique IS2 in treatment of irritable
807 bowel syndrome in children: a double blind, randomised placebo controlled study. *Benef.*
808 *Microbes* 9, 563–572 (2018).
- 809 26. Sudha, R. M., Yelikar, K. A. & Deshpande, S. Clinical study of *Bacillus*
810 *coagulans* Unique IS-2 (ATCC PTA-11748) in the treatment of patients with bacterial
811 vaginosis. *Indian J. Microbiol.* 52, 396–399 (2012).
- 812 27. Madempudi, R. S. *et al.* *Bacillus coagulans* Unique IS2 in constipation: a double-blind,
813 placebo-controlled study. *Probiotics Antimicrob. Proteins*,
814 <https://doi.org/10.1007/s12602-019-09542-9> (2019).
- 815 28. Walmsley, R. S., Ayres, R. C. S., Pounder, R. E., & Allan, R. N. (1998). *A simple*
816 *clinical colitis activity index*. *Gut*, 43(1), 29–32. doi:10.1136/gut.43.1.29
- 817 29. Derogatis, L. R. e. a., et al. (1974). The Hopkins Symptom Checklist (HSCL): A measure
818 of primary symptom dimensions. In P. Pichot & R. Olivier-Martin (Eds.), *Psychological*
819 *measurements in psychopharmacology*. S. Karger. <https://doi.org/10.1159/000395070>

- 820 30. Kleppang, A. L., & Hagquist, C. (2016). The psychometric properties of the Hopkins
821 Symptom Checklist-10: a Rasch analysis based on adolescent data from Norway. *Family*
822 *Practice*, 33(6), 740–745. doi:10.1093/fampra/cmw091
- 823 31. Ahmed Nihal, Daniel Betty, Varghese Jancy, Evangeline Rachael, Jose Tony.
824 "Oropharyngeal microbiome of an HIV-positive patient", *Microbial Pathogenesis*, 2020:
825 <https://doi.org/10.1016/j.micpath.2019.103805>
- 826 32. Hudson LE, Anderson SE, Corbett AH, Lamb TJ. Gleaning insights from fecal
827 microbiota transplantation and probiotic studies for the rational design of combination
828 microbial therapies. *Clin Microb Rev* 2017; 30:191–231. doi: 10.1128/CMR.00049-16.
- 829 33. Cao Jiang, YucZhiming, LiuaWenyin, ZhaoaJianxin, ZhangaHao, ZhaiaQixiao, Chena
830 Wei, ; Probiotic characteristics of *Bacillus coagulans* and associated implications for
831 human health and diseases; *Journal of Functional Foods* 64 (2020) 103643;
832 <https://doi.org/10.1016/j.jff.2019.103643>
- 833 34. Hyronimus, B., Marrec, C. L., Sassi, A. H., & Deschamps, A. (2000). Acid and bile
834 tolerance of spore-forming lactic acid bacteria. *Int J of Food Microb*, 61(2), 193–197.
- 835 34. Upadrasta, A., Pitta, S. and Madempudi, R.S., 2016. Draft genome sequence of the
836 spore-forming probiotic strain *Bacillus coagulans* Unique IS-2. *Genome Announc*, 4(2),
837 pp.e00225-16.
- 838 35. Keller, D., Verbruggen, S., Cash, H., Farmer, S., & Venema, K. (2019). Spores of
839 *Bacillus coagulans* GBI-30, 6086 show high germination, survival and enzyme activity
840 in a dynamic, computer-controlled in vitro model of the gastrointestinal tract. *Beneficial*
841 *Microbes*, 10(1), 77–87.
- 842 35. Saneian, H. *et al.* Synbiotic containing *Bacillus coagulans* and fructo-oligosaccharides for
843 functional abdominal pain in children. *Gastro Hepatol. Bed Bench* 8, 56–65 (2015).
- 844 36. Pawar, R. R., Pardeshi, M. L. & Ghongane, B. B. Study of effects of probiotic lactobacilli
845 in preventing major complications in patients of liver cirrhosis. *Int. J. Res. Pharma.*
846 *Biomed. Sci.* 3, 206–211 (2012).
- 847 37. Sudha, M. R. & Arunasree, K. M. Anti-inflammatory and immunomodulatory effects of
848 *Bacillus coagulans* Unique IS2. *Int. J. Probiotics Prebiotics* 10, 31–36 (2015).
- 849 38. Madempudi Sudha R & Kalle Arunasree M. (2017): Anti-proliferative Effects of
850 *Bacillus coagulans* Unique IS2 in Colon Cancer Cells, *Nutrition and Cancer*, DOI:
851 10.1080/01635581.2017.1359317
- 852 39. Kho ZY and Lal SK (2018) The Human Gut Microbiome – A Potential Controller of
853 Wellness and Disease. *Front. Microbiol.* 9:1835. doi: 10.3389/fmicb.2018.01835
- 854 40. Susanne H, Newberry S J, Maher A R, Zhen W, Miles J. N. V., Roberta S, Shekelle P. G.
855 (2012). Probiotics for the prevention and treatment of antibiotic-associated diarrhea: A
856 systematic review and meta-analysis. *Jama the Journal of the American Medical*
857 *Association*, 307(18), 1959–1969.
- 858 41. Ara K, Meguro S, Hase T, Tokimitsu I, Otsuji K, Kawai S, Iino H. (2002). Effect of
859 spore-bearing lactic acid-forming bacteria (*B coagulans* SANK 70258) administration on
860 the intestinal environment, defecation frequency, fecal characteristics and dermal
861 characteristics in humans and rats. *Microb Ecology in Health & Disease*, 14(1), 4–13.

- 862 42. Jain Abhishek, Li Xin Hui and Chen Wei Ning. Similarities and differences in gut
863 microbiome composition correlate with dietary patterns of Indian and Chinese adults
864 *AMB Expr* (2018) 8:104 <https://doi.org/10.1186/s13568-018-0632-1>
- 865 43. Gupta A, Dhakan DB, Maji A, Saxena R, PK VP, Mahajan S, Pulikkan J, Kurian J,
866 Gomez AM, Scaria J, Amato KR, Sharma AK, Sharma VK. 2019. Association of
867 *Flavonifractor plautii*, a flavonoid-degrading bacterium, with the gut microbiome of
868 colorectal cancer patients in India. *mSystems* 4:e00438-19.DOI:
869 10.1128/mSystems.00438-19
- 870 44. Ryan FJ, Ahern AM, Fitzgerald RS, Laserna-Mendieta EJ, Power EM, Clooney AG,
871 O'Donoghue KW, et al Colonic microbiota is associated with inflammation and host
872 epigenomic alterations in inflammatory bowel disease. *Nat Commun* 2020; 11: 1512
873 [PMID: 32251296 DOI: 10.1038/s41467-020-15342-5]
- 874 45. Bamola V. Deepak, Ghosh Arnab, Kapardar Raj Kishor, Lal Banwari, Cheema Simrita,
875 Sarma Priyangshu & Chaudhry Rama (2017) Gut microbial diversity in health and
876 disease: experience of healthy Indian subjects, and colon carcinoma and inflammatory
877 bowel disease patients, *Microbial Ecology in Health and Disease*, 28:1, 1322447
878 DOI:10.1080/16512235.2017.1322447
- 879 46. Josephine Ni, Gary D. Wu, Lindsey Albenberg and Vesselin T. Tomov (2017): Gut
880 microbiota and IBD: causation or correlation?: *Nature Reviews : Gastroenterology &*
881 *Hepatology* Volume 14 | October 2017 | 573 doi:10.1038/nrgastro.2017.88
- 882 47. Feng Qiang, Liang Suisha, Jia Huijue, Stadlmayr Andreas, Tang Longqing, Lan Zhou,
883 Zhang Dongya (2015); Gut microbiome development along the colorectal adenoma-
884 carcinoma sequence. *Nat Com* 2015; 6:6528; [DOI: 10.1038/ncomms7528]
- 885 48. Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of complex
886 carbohydrates in the gut. *Gut Microbes*. 2012 Jul 14; 3(4):289±306.
887 [DOI:10.4161/gmic.19897]
- 888 49. Becker C, Neurath MF, Wirtz S. The Intestinal Microbiota in Inflammatory Bowel
889 Disease. *ILAR J* 2015;56: 192-204 [PMID: 26323629 DOI: 10.1093/ilar/ilv030]
- 890 50. Wang W, Chen L, Zhou R, Wang X, Song L, Huang S, Wang G, Xia B. Increased
891 proportions of *Bifidobacterium* and the *Lactobacillus* group and loss of butyrate-
892 producing bacteria in inflammatory bowel disease. *J Clin Microbiol* 2014; 52: 398-406
893 [PMID: 24478468 DOI: 10.1128/JCM.01500-13]
- 894 51. Joossens, M.; Huys, G.; Cnockaert, M.; De Preter, V.; Verbeke, K.; Rutgeerts, P.;
895 Vandamme, P.; Vermeire, S. Dysbiosis of the faecal microbiota in patients with Crohn's
896 disease and their unaffected relatives. *Gut* 2011, 60, 631–637.
- 897 52. Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermudez-Humaran, L. G.,
898 Gratadoux, J. J., et al. (2008). *Faecalibacterium prausnitzii* is an anti-inflammatory
899 commensal bacterium identified by gut microbiota analysis of Crohn disease patients.
900 *Proc. Natl. Acad. Sci. U.S.A.* 105, 16731–16736. doi: 10.1073/pnas.0804812105
- 901 53. Nemoto, H.; Kataoka, K.; Ishikawa, H.; Ikata, K.; Arimochi, H.; Iwasaki, T.; Yasutomo,
902 K. Reduced diversity and imbalance of fecal microbiota in patients with ulcerative
903 colitis. *Dig. Dis. Sci.* 2012, 57, 2955–2964.

- 904 54. Gevers D, Kugathasan S, Denson LA, Vazquez-Baeza Y, Van Treuren W, Ren B, et al.
905 The treatment-naïve microbiome in new-onset Crohn's disease. *Cell Host Microbe*
906 2014;15:382-92.
- 907 55. Schirmer M, Franzosa EA, Lloyd-Price J, McIver LJ, Schwager R, Poon TW, et al.
908 Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. *Nat*
909 *Microbiol* 2018;3:337-46.
- 910 56. Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., et al.
911 (2011). Enterotypes of the human gut microbiome. *Nature* 473:174. [DOI:
912 10.1038/nature09944]
- 913 57. Bennet, S. M. *et al.* Global cytokine profiles and association with clinical characteristics
914 in patients with irritable bowel syndrome. *Am. J. Gastroenterol.* 111, 1165–1176 (2016).
- 915 58. Braat, H., Rottiers, P., Hommes, D. W., Huyghebaert, N., Remaut, E., Remon, J. P., et al.
916 (2006). A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's
917 disease. *Clin. Gastroenterol. Hepatol.* 4, 754–759. doi: 10.1016/j.cgh. 2006.03.028
- 918 59. Mitsuyama, K., Tomiyasu, N., Takaki, K., Masuda, J., Yamasaki, H., Kuwaki, K., Sata,
919 M. (2006). Interleukin-10 in the Pathophysiology of Inflammatory Bowel Disease:
920 Increased Serum Concentrations During the Recovery Phase. *Mediators of Inflammation*,
921 2006, 1–7. doi:10.1155/mi/2006/26875
- 922 60. Xiaojing Ma, Wenjun Yan, Hua Zheng, Qinglin Du, Lixing Zhang, Yi Ban, NaLi,
923 and Fang Wei(2015): Regulation of IL-10 and IL-12 production and function in
924 macrophages and dendritic cells; 4: F1000 Faculty Rev-1465.
925 doi: [10.12688/f1000research.7010.1](https://doi.org/10.12688/f1000research.7010.1)
- 926 61. Mavropoulou Eirini, Mechie Nicolae-Catalin, Knoop Richard, PetzoldGolo, Ellenrieder
927 Volker, Kunsch Steffen, PilavakisYiannis, Amanzada Ahmad (2020): Association of
928 serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status
929 in patients with inflammatory bowel disease: A prospective observational study: *PLoS*
930 *ONE* 15(5): e0233811. <https://doi.org/10.1371/journal.pone.0233811>
- 931 62. Holtkamp W, StollbergT, Reis H E (1995); Serum interleukin-6 is related to disease
932 activity but not disease specificity in inflammatory bowel disease: *J ClinGastroenterol*:
933 1995 Mar;20 (2):123-6. DOI: [10.1097/00004836-199503000-00010](https://doi.org/10.1097/00004836-199503000-00010)
- 934 63. Kuwabara Taku, Ishikawa Fumio, Kondo Motonari, and KakiuchiTerutaka (2017): The
935 Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases: *Mediators*
936 *of Inflammation* Volume 2017, Article ID 3908061, 11 pages
937 <http://dx.doi.org/10.1155/2017/3908061>
- 938 64. Nemeth Z H, Bogdanovski D A, Barratt-stopper P, et al. (April 19, 2017) Crohn's
939 Disease and Ulcerative Colitis Show Unique Cytokine Profiles. *Cureus* 9(4): e1177. DOI
940 10.7759/cureus.1177
- 941 65. Mao, L., Kitani, A., Strober, W., & Fuss, I. J. (2018). *The Role of NLRP3 and IL-1β in*
942 *the Pathogenesis of Inflammatory Bowel Disease. Frontiers in Immunology,*
943 *9.* doi:10.3389/fimmu.2018.02566
- 944 66. Coccia M, Harrison OJ, Schiering C, Asquith MJ, Becher B, Powrie F, et al. IL-1β
945 mediates chronic intestinal inflammation by promoting the accumulation of IL-17A
946 secreting innate lymphoid cells and CD4+ Th17 cells. *J Exp Med.* (2012) 209:1595–609.
947 doi: 10.1084/jem.20111453

- 948 67. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1in
949 inflammatory bowel disease – enhanced production during active disease. *Gut* (1990)
950 31:686–89.
- 951 68. Marcus, M. M., Jardemark, K., Malmerfelt, A., Gertow, J., Konradsson-Geuken, Å.&
952 Svensson, T. H. (2011). *Augmentation by escitalopram, but not citalopram or R-*
953 *citalopram, of the effects of low-dose risperidone: Behavioral, biochemical, and*
954 *electrophysiological evidence. Synapse, 66(4), 277–290. doi:10.1002/syn.21510*
- 955 69. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, et al. Treatment of
956 relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a
957 standard pharmaceutical treatment: A double-blind, randomized, placebo-controlled
958 study. *Am J Gastroenterol* 2010; 105(10): 2218-2227.
- 959 70. Ganji-Arjenaki M, Rafieian-Kopaei M. Probiotics are a good choice in remission of
960 inflammatory bowel diseases: a meta-analysis and systematic review. *J Cell Physiol*
961 2018; 233:2091–2103. doi: 10.1002/jcp.25911.
- 962 71. Schlee M, Harder J, Kotten B *et al.* Probiotic lactobacilli and VSL # 3 induce enterocyte
963 beta-defensin 2. *ClinExpImmunol* 2008; 151: 528 – 35.
- 964 72. Didari T, Mozaffari S, Nikfar S and Abdollahi M, 2015. Effectiveness of probiotics in
965 irritable bowel syndrome: updated systematic review with meta-analysis. *World Journal*
966 *of Gastroenterology* 21: 3072-3084.
- 967 73. Gareau, M.G., Sherman, P.M. and Walker, W.A., 2010. Probiotics and the gut
968 microbiota in intestinal health and disease. *Nature Reviews Gastroenterology and*
969 *Hepatology* 7: 503-514.
- 970 74. Korterink, J.J., Ockeloen, L., Benninga, M.A., Tabbers, M.M., Hilbink, M. and Deckers-
971 Kocken, J.M., 2014. Probiotics for childhood functional gastrointestinal disorders: a
972 systematic review and meta-analysis. *ActaPaediatrica* 103: 365-372.